Product Overview
[Drug Name]
Generic Name: Piracetam Tablets
Trade Name: Renjitang Piracetam Tablets 0.4g x 100 Tablets
[Main Ingredients]
The main ingredient of this product is: Piracetam.
[Properties]
This product is white tablets.
[Indications/Main Functions]
It is indicated for memory loss and mild to moderate brain dysfunction caused by various causes, including acute and chronic cerebrovascular disease, brain trauma, and various toxic encephalopathy. It can also be used for children with intellectual disability.
[Specifications]
0.4g x 100 tablets
[Dosage and Administration]
Oral administration: 0.8-1.6g (2-4 tablets) three times daily for a course of 4-8 weeks. Children should use half the dose.
[Adverse Reactions]
Common gastrointestinal adverse reactions include nausea, abdominal discomfort, poor appetite, abdominal distension, and abdominal pain. The severity of symptoms is directly related to the dosage. Central nervous system adverse reactions include excitement, irritability, dizziness, headache, and insomnia, but these symptoms are mild and unrelated to dosage. These symptoms disappear after discontinuation of the drug. Mild liver impairment, manifested as mild elevations in transaminases, has occasionally been observed, but this is unrelated to the dosage.
[Contraindications]
This product is contraindicated in patients with extrapyramidal disorders or Huntington's chorea to avoid exacerbating symptoms.
[Drug Interactions]
This product, when used in combination with warfarin, may prolong the prothrombin time and induce inhibition of platelet aggregation. In patients receiving anticoagulant therapy, when coadministered with piracetam, special attention should be paid to clotting times to prevent bleeding risks, and the dosage and administration of the anticoagulant medication should be adjusted.
[Precautions]
Use with caution in patients with hepatic or renal dysfunction, and the dose should be reduced appropriately.
[Pediatric Use]
This product is contraindicated in neonates.
[Use in Elderly Patients]
The information is unknown.
[Overdose]
The information is unknown.
[Pharmacology and Toxicology]
This product is a brain metabolism-enhancing drug belonging to the cyclical group of gamma-aminobutyric acid. It has similar effects on protecting against physical and chemical damage to brain function. It can boost brain ATP, promote acetylcholine synthesis, and positively enhance the conduction of nerve impulses, thus promoting brain metabolism. It can counteract physical and chemical damage to brain function. It also improves retrograde ejaculation caused by hypoxia. It can enhance memory and improve learning ability. Acute toxicity studies in animals showed that oral gavage doses of more than 10g/kg did not cause mortality in mice. The median lethal dose (LD50) after intravenous administration was 9.2g/kg. Subacute and chronic toxicity studies revealed no adverse effects on growth and development in rats and dogs. It also had no effects on vital internal organs or functions, including the blood, heart, liver, kidneys, and brain.
